South Texas Money Management Ltd. cut its stake in shares of Bristol-Myers Squibb Company (NYSE:BMY) by 1.0% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 677,726 shares of the biopharmaceutical company’s stock after selling 7,083 shares during the period. Bristol-Myers Squibb makes up about 1.9% of South Texas Money Management Ltd.’s holdings, making the stock its 15th largest position. South Texas Money Management Ltd.’s holdings in Bristol-Myers Squibb were worth $36,855,000 at the end of the most recent reporting period.

Several other large investors have also recently bought and sold shares of BMY. SNS Financial Group LLC increased its stake in Bristol-Myers Squibb by 73.8% in the fourth quarter. SNS Financial Group LLC now owns 11,423 shares of the biopharmaceutical company’s stock valued at $668,000 after buying an additional 4,852 shares during the last quarter. CMH Wealth Management LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at $1,254,000. AE Wealth Management LLC bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at $325,000. Appaloosa LP bought a new stake in shares of Bristol-Myers Squibb during the fourth quarter valued at $21,915,000. Finally, Willis Investment Counsel increased its stake in shares of Bristol-Myers Squibb by 15.0% in the fourth quarter. Willis Investment Counsel now owns 152,130 shares of the biopharmaceutical company’s stock valued at $8,890,000 after buying an additional 19,801 shares in the last quarter. 69.79% of the stock is owned by institutional investors and hedge funds.

Bristol-Myers Squibb Company (BMY) opened at 55.95 on Monday. The stock has a 50 day moving average price of $55.55 and a 200-day moving average price of $54.50. Bristol-Myers Squibb Company has a 12 month low of $46.01 and a 12 month high of $64.77. The stock has a market cap of $91.75 billion, a PE ratio of 20.43 and a beta of 1.17.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, July 27th. The biopharmaceutical company reported $0.74 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.73 by $0.01. The business had revenue of $5.14 billion during the quarter, compared to analyst estimates of $5.09 billion. Bristol-Myers Squibb had a return on equity of 32.33% and a net margin of 22.66%. The company’s revenue was up 5.6% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.69 earnings per share. On average, analysts expect that Bristol-Myers Squibb Company will post $2.97 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, August 1st. Stockholders of record on Friday, July 7th were issued a $0.39 dividend. The ex-dividend date was Wednesday, July 5th. This represents a $1.56 annualized dividend and a dividend yield of 2.79%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 56.73%.

ILLEGAL ACTIVITY WARNING: “Bristol-Myers Squibb Company (NYSE:BMY) Shares Sold by South Texas Money Management Ltd.” was originally posted by Daily Political and is owned by of Daily Political. If you are accessing this story on another domain, it was stolen and republished in violation of international copyright and trademark legislation. The legal version of this story can be viewed at https://www.dailypolitical.com/2017/08/07/bristol-myers-squibb-company-nysebmy-shares-sold-by-south-texas-money-management-ltd.html.

Several equities research analysts recently weighed in on BMY shares. Vetr raised Bristol-Myers Squibb from a “buy” rating to a “strong-buy” rating and set a $58.88 price target for the company in a report on Monday, June 5th. Jefferies Group LLC reaffirmed a “buy” rating and set a $64.00 price target on shares of Bristol-Myers Squibb in a report on Monday, June 5th. BidaskClub raised Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a report on Tuesday, June 27th. Robert W. Baird started coverage on Bristol-Myers Squibb in a report on Tuesday, April 25th. They set an “outperform” rating for the company. Finally, Deutsche Bank AG set a $55.00 price target on Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Monday, July 17th. Two analysts have rated the stock with a sell rating, eleven have issued a hold rating, eleven have issued a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average price target of $63.33.

In other news, Director Theodore R. Samuels II acquired 6,000 shares of the business’s stock in a transaction dated Wednesday, August 2nd. The stock was acquired at an average price of $55.94 per share, for a total transaction of $335,640.00. Following the completion of the acquisition, the director now directly owns 18,000 shares in the company, valued at approximately $1,006,920. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Corporate insiders own 0.23% of the company’s stock.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb Company and related companies with MarketBeat.com's FREE daily email newsletter.